Hepatocellular carcinoma

Current Opinion in Gastroenterology

Volumn 13, Issue 3, 1997, Pages 257-262

  Macdonald, Graeme A ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA;

DYSPLASIA; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METABOLISM; MALIGNANT TRANSFORMATION; REVIEW;

EID: 0030973555     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199705000-00012     Document Type: Review

References (45)

1. Parkin DM, Stjernsward J, Muir CS: Estimates of the worldwide frequency of twelve major cancers. Bull World Health Organ 1984, 62:163-182.
2. Bressac B, Kew M, Wands J, Ozturk M: Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Semin Liver Dis 1991, 350:429-431.
3. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC: Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Semin Liver Dis 1991, 350:427-428.
4. Cariello NF, Piegorsch WW, Adams WT, Skopek TR: Computer program for the analysis of mutational spectra: application to p53 mutations. Carcinogenesis 1994, 15:2281-2285.
5. McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper ML, Zhou T, Wild • CP, Xia XL, Baffoe Bonnie A, Ofori Adjei D, Chen GC, London WT, Shen FM. Buetow KH: Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci U S A 1995, 92:2384-2387. This paper examines the relationship between two enzymes that detoxify the carcinogenic metabolite of aflatoxin and susceptibility to HCC. It presents the risk of HCC in terms of genotyping of these enzymes, serum markers of aflatoxin exposure, and hepatitis B infection.
6. Puisieux A, Lim S, Groopman J, Ozturk M: Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res 1991, 51:6185-6189.
7. Hayward NK, Walker GJ, Graham W, Cooksley E: Hepatocellular carcinoma mutation [letter]. Nature 1991, 352:764.
8. Kubicka S, Trautwein C, Schrem H, Tillmann H, Manns M: Low incidence of p53 mutations in European hepatocellular carcinomas with heterogeneous mutation as a rare event. J Hepatol 1995, 23:412-419.
9. Fujimoto Y, Hampton LL, Wirth PJ, Wang NJ, Xie JP, Thorgeirsson SS: Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res 1994, 54:281-285.
10. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
11. Kinzler WK. Vogelstein B: Lessons from hereditary colorectal carci•• noma. Cell 1996, 87:159-170. Review article that summarizes the current understanding of colorectal carcinogenesis, including familial cancer syndromes and the DNA mismatch repair system. It incorporates recent progress in the area into the model proposed by Fearon and Vogelstein (Cell 1990, 61:759-767). The successes in determining events in CRC provide a possible guide for future research into HCC.
12. Terminology of nodular hepatocellular lesions: International Working • Party. Hepatology 1995, 22:983-993. Proposes criteria for nomenclature and histologic diagnosis of nodular hepatic lesions. These guidelines will hopefully be widely used so that there will be consistency in the diagnosis of hepatic lesions. This will facilitate comparison of studies from different regions of the world and ultimately improve our understanding of the sequence and timing of genetic events in hepatic carcinogenesis.
13. Aihara T, Noguchi S, Sasaki Y, Nakano H, Monden M, Imaoka S: Clonal • analysis of precancerous lesion of hepatocellular carcinoma. Gastroenterology 1996, 111:455-461. The authors present evidence that dysplastic lesions are neoplastic.
14. Aihara T, Noguchi S, Sasaki Y, Nakano H, Imaoka S: Clonal analysis of regenerative nodules in hepatitis C virus-induced liver cirrhosis. Gastroenterology 1994, 107:1805-1811.
15. Kishimoto Y, Shiota G, Wada K, Kitano M, Nakamoto K, Kamisaki Y, Suou • T, Itoh T, Kawasaki H: Frequent loss in chromosome 8p in liver cirrhosis accompanying hepatocellular carcinoma. J Cancer Res Clin Oncol 1996, 122:585-589. Loss of 8p is an important event in a variety of malignancies. This manuscript adds weight to evidence that genetic changes relevant to malignant transformation begin in cirrhotic liver or possibly even earlier.
16. Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, Hirohashi S, Maeda Y, Tsuruta K, Miyaki M, Nakamura Y: Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res 1992, 52:5368-5372.
17. Fujiwara Y, Ohata H, Kuroki T, Koyama K, Tsuchiya E, Monden M, Nakamura Y: Isolation of a candidate tumor suppressor gene on chromosome 8p21.3-p22 that is homologous to an extracellular domain of the PDGF receptor beta gene. Oncogene 1995, 10:891-895.
18. Yamada T, DeSouza A, Finkelstein S, Reddy R, Jirtle R: Mannose 6-phospate insulin-like growth factor-II receptor: a tumor suppressor gene in human liver cancer associated with viral hepatitis and cirrhosis [abstract]. Hepatology 1996, 24:358A.
19. Macdonald GA, Greenson JK, Saito K, Appelman HD, Boland CR: Loss of the DNA mismatch repair genes hMSH2 and hMLH1 is an early event in hepatic carcinogenesis [abstract]. Hepatology 1995, 22:219A.
20. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL: • Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995, 10:1725-1729 Provides a link between observations about chromosomal loss in HCC and possible mechanisms of carcinogenesis. Presents strong evidence that IGFIIr is a tumor suppressor gene for HCC and shows a link between LOH events and mitogenic pathways.
21. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL: • M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nature Genet 1995, 11:447-449. Provides a link between observations about chromosomal loss in HCC and possible mechanisms of carcinogenesis. Presents strong evidence that IGFIIr is a tumor suppressor gene for HCC and shows a link between LOH events and mitogenic pathways.
22. LeRoith D, Baserga R, Helman L, Roberts CT Jr: Insulin-like growth factors and cancer. Ann Intern Med 1995, 122:54-59.
23. Kim SO, Park JG, Lee YI: Increased expression of the insulin-like growth factor I (IGF-1) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-1 receptor gene activation by hepatitis B virus X gene product Cancer Res 1996, 56.3831-3836.
24. Morgan DO, Edman JC, Standring DN, Fried VA, Smith MC, Roth RA, Rutter WJ: Insulin-like growth factor II receptor as a multifunctional binding protein. Nature 1987, 329:301-307.
25. Dennis PA, Rifkin DB: Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci U S A 1991, 88:580-584.
26. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J: Mechanism of activation of the TGF-beta receptor. Nature 1994, 370:341-347.
27. Sue SR, Chari RS, Kong FM, Mills JJ, Fine RL, Jirtle RL, Meyers W: Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma. Ann Surg 1995, 222:171-178.
28. Bedossa P, Peltier E, Terris B, Franco D, Poynard T: Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 1995, 21:760-766.
29. Sohda T, Yun K, Iwata K, Soejima H, Okumura M: Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. Lab Invest 1996, 75:307-311.
30. Nardone G, Romano M, Calabro A, Pedone PV, de Sio I, Persico M, Budillon G, Bruni CB, Riccio A, Zarrilli R: Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatology 1996, 23:1304-1312.
31. Tanaka S, Ito T, Wands JR: Neoplastic transformation induced by insulin receptor substrate-1 overexpression requires an interaction with both Grb2 and Syp signaling molecules. J Biol Chem 1996. 271:14610-14616.
32. Ito T, Sasaki Y, Wands JR: Overexpression of human insulin receptor substrate 1 induces cellular transformation with activation of mitogen-activated protein kinases. Mol Cell Biol 1996, 16:943-951.
33. Nishiyama M, Wands JR: Cloning and increased expression of an insulin receptor substrate-1-like gene in human hepatocellular carcinoma. Biochem Biophys Res Commun 1992, 183:280-285.
34. Tanaka S, Wands JR: Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis. Cancer Res 1996, 56:3391-3394.
35. Ganne-Carrie N, Chastang C, Chapel F, Munz C, Pateron D, Sibony M, • Deny P, Trinchet JC, Callard P, Guettier C, Beaugrand M: Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology 1996, 23:1112-1118. Shows that dysplasia, present on liver biopsy, can be combined with clinical parameters to identify patients with increased risk of HCC. This finding has implications for treatment options for these patients.
36. Borzio M, Bruno S, Roncalli M, Mels GC, Ramella G, Borzio F, Leandro G, Servida E, Podda M: Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology 1995, 108:812-817.
37. Borzio M, Bruno S, Roncalli M, Mels GC, Ramella G, Borzio F, Leandro G, Podda M: Liver cell dysplasia and risk of hepatocellular carcinoma in cirrhosis: a preliminary report BMJ 1991, 302:1312.
38. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, • Shiomi S, Seki S, Kobayashi K, Otani S: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995, 346:1051-1055. Suggests that treatment of hepatitis C-related cirrhosis with interferon may reduce the risk of developing HCC. This is a controversial finding, and the implications for treatment of patients with cirrhosis due to hepatitis C and the discussion provoked are of interest.
39. Sharara AI, Hunt CM, Hamilton JD: Hepatitis C. Ann Intern Med 1996, 125:658-668.
40. Harper SE, Dienstag JL: Can Interferon alfa treatment prevent hepatocellular carcinoma in patients with chronic hepatitis C infection and compensated cirrhosis? Hepatology 1996, 23:930-933.
41. Andreone P, Cursaro C, Gramenzi A, Trevisani F, Gasbarrini G, Bernardi M: Interferon and hepatocellular carcinoma [letter]. Lancet 1996, 347:195.
42. Koretz RL: Interferon and hepatocellular carcinoma. Lancet 1996, 347:194-195.
43. Grimm I, Shaheen N: Can Interferon prevent hepatocellular carcinoma in hepatitis C virus-induced cirrhosis? Gastroenterology 1996, 110:2019-2021.
44. Schluger LK, Bodenheimer H Jr: Tackling liver cancer with interferon. Lancet 1995, 346:1049-1050.
45. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, • Cippolla A, Fabbri C, Pezzoli A, Roda E: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996, 24:141-147. Suggests that treatment of hepatitis C-related cirrhosis with interferon may reduce the risk of developing HCC. This is a controversial finding, and the implications for treatment of patients with cirrhosis due to hepatitis C and the discussion provoked are of interest.